Mutations within the tumour suppressor gene p53 are not confined to a late event in prostate cancer progression: a review of the evidence

被引:33
作者
Downing, SR
Jackson, P
Russell, PJ
机构
[1] Prince Wales Hosp, Oncol Res Ctr, Randwick, NSW 2031, Australia
[2] Univ New S Wales, Fac Med, Kensington, NSW 2033, Australia
来源
UROLOGIC ONCOLOGY | 2001年 / 6卷 / 03期
关键词
p53; mutations; prostate cancer; tumour progression;
D O I
10.1016/S1078-1439(00)00119-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Mutations in the p53 tumour suppressor gene are generally believed to be a late event in the progression of prostate cancer, and are associated with androgen independence, metastasis. and a worse prognosis. In this review, we examine the current literature available on p53 mutations and focus on stages A (T1) and B (T2) of prostate cancer. We report here that p53 mutations can he found in approximately one third of prostate cancers that are clinically localized to the prostate. In addition, high levels of p53 mutation are found in normal prostate tissue of prostate cancer patients, prostatic intracpithelial neoplasia, and benign prostatic hyperplasia. The limitations of techniques used to determine p53 mutations are discussed. as well as other modes of p53 loss in early stage prostate cancer. (C) 2001 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:103 / 110
页数:8
相关论文
共 130 条
  • [31] LOSS OF HETEROZYGOSITY AND OVEREXPRESSION OF P53 GENE IN HUMAN PRIMARY PROSTATIC ADENOCARCINOMA
    FAN, K
    DAO, DD
    SCHUTZ, M
    FINK, LM
    [J]. DIAGNOSTIC MOLECULAR PATHOLOGY, 1994, 3 (04) : 265 - 270
  • [32] P53 AND C-MYC EXPRESSION IN STAGE A1 PROSTATIC ADENOCARCINOMA - USEFUL PROGNOSTIC DETERMINANTS
    FOX, SB
    PERSAD, RA
    ROYDS, J
    KORE, RN
    SILCOCKS, PB
    COLLINS, CC
    [J]. JOURNAL OF UROLOGY, 1993, 150 (02) : 490 - 494
  • [33] Mdm2 association with p53 targets its ubiquitination
    Fuchs, SY
    Adler, V
    Buschmann, T
    Wu, XW
    Ronai, Z
    [J]. ONCOGENE, 1998, 17 (19) : 2543 - 2547
  • [34] Gao X, 1997, ADV EXP MED BIOL, V407, P41
  • [35] A transgenic mouse model of metastatic prostate cancer originating from neuroendocrine cells
    Garabedian, EM
    Humphrey, PA
    Gordon, JI
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (26) : 15382 - 15387
  • [36] GIGNON DJ, 1997, JNCI-J NATL CANCER I, V89, P158
  • [37] Gingrich JR, 1996, CANCER RES, V56, P4096
  • [38] Gingrich JR, 1997, CANCER RES, V57, P4687
  • [39] Green JE, 1998, PROSTATE, V36, P59, DOI 10.1002/(SICI)1097-0045(19980615)36:1<59::AID-PROS11>3.0.CO
  • [40] 2-H